EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 33 / Numéro 10 (Octobre 2017) Med Sci (Paris), 33 10 (2017) 871-877 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 33, Numéro 10, Octobre 2017
Page(s) 871 - 877
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20173310019
Publié en ligne 10 octobre 2017
  1. Merle NS, Church SE, Fremeaux-Bacchi V, et al. Complement system part I. Molecular mechanisms of activation and regulation. Front Immunol 2015; 6 : 262. [PubMed] [Google Scholar]
  2. Merle NS, Noe R, Halbwachs-Mecarelli L, et al. Complement system part II: role in immunity. Front Immunol 2015 ; 6 : 257. [PubMed] [Google Scholar]
  3. Gaboriaud C, Ling WL, Thielens NM, et al. Deciphering the fine details of c1 assembly and activation mechanisms: “mission impossible”?. Front Immunol 2014 ; 5 : 565. [CrossRef] [PubMed] [Google Scholar]
  4. Bonavita E, Gentile S, Rubino M, et al. PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell 2015 ; 160 : 700–714. [CrossRef] [PubMed] [Google Scholar]
  5. Nauta AJ, Trouw LA, Daha MR, et al. Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur J Immunol 2002 ; 32 : 1726–1736. [CrossRef] [PubMed] [Google Scholar]
  6. Dobó J, Pál G, Cervenak L, et al. The emerging roles of mannose-binding lectin-associated serine proteases (MASPs) in the lectin pathway of complement and beyond. Immunol Rev 2016 ; 274 : 98–111. [CrossRef] [PubMed] [Google Scholar]
  7. Ricklin D, Reis ES, Mastellos DC, et al. Complement component C3 - The “Swiss Army Knife” of innate immunity and host defense. Immunol Rev 2016 ; 274 : 33–58. [CrossRef] [PubMed] [Google Scholar]
  8. Morgan BP, Walters D, Serna M, et al. Terminal complexes of the complement system: new structural insights and their relevance to function. Immunol Rev 2016 ; 274 : 141–151. [CrossRef] [PubMed] [Google Scholar]
  9. Chauvet S, Marinozzi MC, Le Quintrec M, et al. Spectre des anomalies du complément associées aux glomérulopathies à dépôts de C3: quoi de neuf en 2014 ?. Néphrologie Thérapeutique 2014 ; 10 : 280–281. [CrossRef] [Google Scholar]
  10. Ricklin D, Reis ES, Lambris JD. Complement in disease: a defence system turning offensive. Nat Rev Nephrol 2016 ; 12 : 383–401. [CrossRef] [PubMed] [Google Scholar]
  11. Ajona D, Pajares MJ, Corrales L, et al. Investigation of complement activation product C4d as a diagnostic and prognostic biomarker for lung cancer. J Natl Cancer Inst 2013 ; 105 : 1385–1393. [CrossRef] [PubMed] [Google Scholar]
  12. Imamura T, Yamamoto-Ibusuki M, Sueta A, et al. Influence of the C5a–C5a receptor system on breast cancer progression and patient prognosis. Breast Cancer Tokyo Jpn 2016 ; 23 : 876–885. [CrossRef] [Google Scholar]
  13. Chen J, Wu W, Chen L, et al. Expression and clinical significance of AHSG and complement C3 in pancreatic ductal adenocarcinoma. Zhonghua Yi Xue Za Zhi 2014 ; 94 : 2175–2179. [PubMed] [Google Scholar]
  14. Xi W, Liu L, Wang J, et al. High level of anaphylatoxin C5a predicts poor clinical outcome in patients with clear cell renal cell carcinoma. Sci Rep 2016 ; 6 : 29177. [CrossRef] [PubMed] [Google Scholar]
  15. Chang IW, Lin VCH, Wu WJ, et al. Complement component 1, s subcomponent overexpression is an independent poor prognostic indicator in patients with urothelial carcinomas of the upper urinary tract and urinary bladder. J Cancer 2016 ; 7 : 1396–1405. [CrossRef] [PubMed] [Google Scholar]
  16. Riihilä PM, Nissinen LM, Ala-aho R, et al. Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma. J Invest Dermatol 2014 ; 134 : 498–506. [CrossRef] [PubMed] [Google Scholar]
  17. Fishelson Z, Donin N, Zell S, et al. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003 ; 40 : 109–123. [Google Scholar]
  18. Cho MS, Vasquez HG, Rupaimoole R, et al. Autocrine effects of tumor-derived complement. Cell Rep 2014 ; 6 : 1085–1095. [CrossRef] [PubMed] [Google Scholar]
  19. Hong Q, Sze CI, Lin SR, et al. Complement C1q activates tumor suppressor WWOX to induce apoptosis in prostate cancer cells. PLoS One 2009 ; 4 : e5755. [CrossRef] [PubMed] [Google Scholar]
  20. Maeda Y, Kawano Y, Wada Y, et al. C5aR is frequently expressed in metastatic renal cell carcinoma and plays a crucial role in cell invasion via the ERK and PI3 kinase pathways. Oncol Rep 2015 ; 33 : 1844–1850. [CrossRef] [PubMed] [Google Scholar]
  21. Lu Y, Hu XB. C5a stimulates the proliferation of breast cancer cells via Akt-dependent RGC-32 gene activation. Oncol Rep 2014 ; 32 : 2817–2823. [CrossRef] [PubMed] [Google Scholar]
  22. Cho MS, Rupaimoole R, Choi HJ, et al. Complement component 3 is regulated by TWIST1 and mediates epithelial-mesenchymal transition. J Immunol 2016 ; 196 : 1412–1418. [CrossRef] [PubMed] [Google Scholar]
  23. Piao C, Cai L, Qiu S, et al. Complement 5a enhances hepatic metastases of colon cancer via monocyte chemoattractant protein-1-mediated inflammatory cell infiltration. J Biol Chem 2015 ; 290 : 10667–10676. [CrossRef] [PubMed] [Google Scholar]
  24. Kaida T, Nitta H, Kitano Y, et al. C5a receptor (CD88) promotes motility and invasiveness of gastric cancer by activating RhoA. Oncotarget 2016 ; 7 : 84798–84809. [CrossRef] [PubMed] [Google Scholar]
  25. Nitta H, Murakami Y, Wada Y, et al. Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness. Oncol Rep 2014 ; 32 : 1715–1719. [CrossRef] [PubMed] [Google Scholar]
  26. Bulla R, Tripodo C, Rami D, et al. C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. Nat Commun 2016 ; 7 : 10346. [CrossRef] [PubMed] [Google Scholar]
  27. Rozanov DV, Sikora S, Godzik A, et al. Non-proteolytic, receptor/ligand interactions associate cellular membrane type-1 matrix metalloproteinase with the complement component C1q. J Biol Chem 2004 ; 279 : 50321–50328. [CrossRef] [PubMed] [Google Scholar]
  28. Vlaicu SI, Tegla CA, Cudrici CD, et al. Role of C5b–9 complement complex and response gene to complement-32 (RGC-32) in cancer. Immunol Res 2013 ; 56 : 109–121. [CrossRef] [PubMed] [Google Scholar]
  29. Kaur A, Sultan SHA, Murugaiah V, et al. Human C1q induces apoptosis in an ovarian cancer cell line via tumor necrosis factor pathway. Front Immunol 2016; 7. [Google Scholar]
  30. Nabizadeh JA, Manthey HD, Steyn FJ, et al. The Complement C3a receptor contributes to melanoma tumorigenesis by inhibiting neutrophil and CD4+ T cell responses. J Immunol 2016 ; 196 : 4783–4792. [CrossRef] [PubMed] [Google Scholar]
  31. Janelle V, Langlois M-P, Tarrab E, et al. Transient complement inhibition promotes a tumor-specific immune response through the implication of natural killer cells. Cancer Immunol Res. 2014 ; 2 : 200–206. [CrossRef] [PubMed] [Google Scholar]
  32. Markiewski MM, DeAngelis RA, Benencia F, et al. Modulation of the antitumor immune response by complement. Nat Immunol 2008 ; 9 : 1225–1235. [CrossRef] [PubMed] [Google Scholar]
  33. Corrales L, Ajona D, Rafail S, et al. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol 2012 ; 189 : 4674–4683. [CrossRef] [PubMed] [Google Scholar]
  34. Gunn L, Ding C, Liu M, et al. Opposing roles for complement component C5a in tumor progression and the tumor microenvironment. J Immunol 2012 ; 189 : 2985–2994. [CrossRef] [PubMed] [Google Scholar]
  35. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003 ; 9 : 653–660. [CrossRef] [PubMed] [Google Scholar]
  36. Singh J, Ahmed A, Girardi G. Role of complement component C1q in the onset of preeclampsia in mice. Hypertension 2011 ; 58 : 7162–7164. [Google Scholar]
  37. Bossi F, Tripodo C, Rizzi L, et al. C1q as a unique player in angiogenesis with therapeutic implication in wound healing. Proc Natl Acad Sci USA 2014 ; 111 : 420914. [CrossRef] [Google Scholar]
  38. Nunez-Cruz S, Gimotty PA, Guerra MW, et al. Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia 2012; 14 : 994-IN1. [Google Scholar]
  39. Rogers LM, Veeramani S, Weiner GJ. Complement in monoclonal antibody therapy of cancer. Immunol Res 2014 ; 59 : 203–210. [CrossRef] [PubMed] [Google Scholar]
  40. Meyer S, Leusen JH, Boross P. Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer. mAbs 2014; 6 : 1133–1144. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.